Suvorexant - Merck & Co
Alternative Names: Belsomra; MK-4305Latest Information Update: 05 Nov 2023
At a glance
- Originator Merck & Co
- Class Azepines; Sleep disorder therapies; Small molecules; Triazoles
- Mechanism of Action Orexin receptor type 1 antagonists; Orexin receptor type 2 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Insomnia
- Phase III Delirium
Most Recent Events
- 23 Dec 2022 Merck Sharp & Dohme completes a phase III trial in Delirium (In the elderly) in Japan (PO) (NCT04571944)
- 28 Nov 2022 Suvorexant is still in phase III trial forDelirium (In the elderly) in Japan (PO) (NCT04571944)
- 22 Oct 2020 Phase-III clinical trials in Delirium (In the elderly) in Japan (PO) (NCT04571944)